+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel, Route of Administration, Drug Class, Formulation, End User - Global Forecast to 2030- Product Image
Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel, Route of Administration, Drug Class, Formulation, End User - Global Forecast to 2030- Product Image
Sale

Non-steroidal Anti-inflammatory Drugs Market by Distribution Channel, Route of Administration, Drug Class, Formulation, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5666179
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The non-steroidal anti-inflammatory drugs (NSAID) market is evolving in response to increased global demand for safer pain management solutions. Emerging trends in product innovation, evolving regulatory landscapes, and an emphasis on patient outcomes are reshaping industry strategies and competitive positioning for senior decision-makers.

Market Snapshot: Non-Steroidal Anti-Inflammatory Drugs Market

The Non-steroidal Anti-inflammatory Drugs Market grew from USD 23.24 billion in 2024 to USD 25.06 billion in 2025. The market is projected to expand at a CAGR of 7.63%, reaching USD 36.13 billion by 2030. This growth reflects ongoing investment in innovative drug formulations, regulatory shifts favoring safer alternatives, and an expanding patient pool across both developed and emerging geographies.

Scope & Segmentation

  • Distribution Channel: Over The Counter, Prescription
  • Route Of Administration: Oral, Parenteral, Topical
  • Drug Class: COX-2 Inhibitors, Nonselective COX Inhibitors
  • Formulation: Capsules, Creams, Gels, Powders, Suspensions, Tablets, Transdermal Patches
  • End User: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
  • Regional Coverage: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Saudi Arabia, South Africa, and others), Asia-Pacific (including China, India, Japan, Australia, South Korea, and others)
  • Leading Companies: Pfizer Inc., Bayer Aktiengesellschaft, Johnson & Johnson, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Viatris Inc.

Key Takeaways for Senior Decision-Makers

  • Strong demand for non-opioid analgesics is driving significant R&D and portfolio diversification among leading manufacturers and specialty firms.
  • Digital health integration, including patient adherence trackers and telemedicine, is opening new channels for engagement and real-time data capture.
  • Value-based contracts and real-world evidence initiatives are increasingly shaping reimbursement strategies, especially under tightening healthcare budgets.
  • Advanced drug delivery technologies are supporting differentiated product offerings by improving patient convenience and targeting site-specific inflammation.
  • Environmental sustainability and greener manufacturing processes are gaining regulatory priority and shaping procurement decisions across the value chain.

Tariff Impact and Supply Chain Dynamics

Recent changes to United States tariff policies have disrupted the NSAID supply chain by increasing costs on imported raw materials from key markets in Europe and Asia. In response, manufacturers are shifting toward domestic synthesis, pursuing local partnerships, and renegotiating contracts. These upstream shifts have affected downstream pricing and prompted the adoption of tiered pricing models and volume-based incentives. Companies adapting quickly with diversified supplier networks are maintaining price competitiveness, while those dependent on single-source imports face margin pressures. The evolving tariff environment is expected to encourage further localization and strategic alliances, strengthening resilience to future geopolitical risk.

Methodology & Data Sources

This analysis incorporates primary interviews with senior industry stakeholders and key opinion leaders, providing strategic insights into clinical, operational, and procurement trends. Secondary research covers peer-reviewed literature, regulatory filings, industry reports, and exclusive data sets. Rigorous triangulation and internal quality controls validate the integrity of all findings and ensure actionable relevance for decision-making.

Why This Report Matters

  • Supports tailored strategy development by offering clear market segmentation and in-depth analysis of distribution, formulation, and end-user trends.
  • Informs risk management and supplier diversification efforts with comprehensive evaluation of tariff impacts and regional market shifts.
  • Equips decision-makers with actionable recommendations aligned to current regulatory expectations, digital innovation, and sustainability requirements.

Conclusion

As the NSAID market landscape continues to transform, companies that anticipate regulatory, technological, and geopolitical developments will be positioned for growth. Strategic adaptation and evidence-based execution will be critical in capturing market opportunities and ensuring long-term competitiveness.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Non-steroidal Anti-inflammatory Drugs Market, by Distribution Channel
8.1. Introduction
8.2. Over the Counter
8.3. Prescription
9. Non-steroidal Anti-inflammatory Drugs Market, by Route of Administration
9.1. Introduction
9.2. Oral
9.3. Parenteral
9.4. Topical
10. Non-steroidal Anti-inflammatory Drugs Market, by Drug Class
10.1. Introduction
10.2. COX-2 Inhibitors
10.3. Nonselective COX Inhibitors
11. Non-steroidal Anti-inflammatory Drugs Market, by Formulation
11.1. Introduction
11.2. Capsules
11.3. Creams
11.4. Gels
11.5. Powders
11.6. Suspensions
11.7. Tablets
11.8. Transdermal Patches
12. Non-steroidal Anti-inflammatory Drugs Market, by End User
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Non-steroidal Anti-inflammatory Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Non-steroidal Anti-inflammatory Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Non-steroidal Anti-inflammatory Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. Bayer Aktiengesellschaft
16.3.3. Johnson & Johnson
16.3.4. Novartis AG
16.3.5. GlaxoSmithKline plc
16.3.6. Teva Pharmaceutical Industries Ltd.
16.3.7. Sandoz International GmbH
16.3.8. Sun Pharmaceutical Industries Ltd.
16.3.9. Merck & Co., Inc.
16.3.10. Viatris Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET MULTI-CURRENCY
FIGURE 2. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NONSELECTIVE COX INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 40. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 43. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 44. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 47. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 48. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 49. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 64. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 70. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 74. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 75. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 80. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 84. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 85. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 90. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 95. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 99. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 100. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 105. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 110. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 114. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 115. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 120. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 125. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 130. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 135. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 145. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 150. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 160. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 164. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 165. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 170. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 177. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 180. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 181. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 186. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 191. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 195. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 196. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 200. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 201. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 205. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 206. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 211. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 215. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 216. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 220. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 221. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 225. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 226. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 230. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 231. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 235. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 236. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
TABLE 238. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Non-steroidal Anti-inflammatory Drugs market report include:
  • Pfizer Inc.
  • Bayer Aktiengesellschaft
  • Johnson & Johnson
  • Novartis AG
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 25.06 Billion
Forecasted Market Value ( USD ) by 2030 $ 36.13 Billion
Compound Annual Growth Rate7.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Route Of Administration, Product Type, Distribution Channel, End User, Indication - Global Forecast to 2030 - Product Image

Dermatological Non-Steroidal Anti-Inflammatory Drugs Market by Route Of Administration, Product Type, Distribution Channel, End User, Indication - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Non-Steroidal Anti-Inflammatory Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Non-Steroidal Anti-Inflammatory Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Non-steroidal Anti-inflammatory Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Non-steroidal Anti-inflammatory Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 101 Pages
  • Global
From
Non-Steroidal Anti-inflammatory Drugs Market Report 2025 - Product Image

Non-Steroidal Anti-inflammatory Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Market

Over the Counter (OTC) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are a class of medications used to reduce inflammation and pain. They are available without a prescription and are used to treat a variety of conditions, including headaches, muscle aches, arthritis, and menstrual cramps. NSAIDs work by blocking the production of certain chemicals in the body that cause inflammation and pain. Common OTC NSAIDs include ibuprofen, naproxen, and aspirin. NSAIDs are generally safe and effective when taken as directed. However, they can cause side effects, such as stomach upset, nausea, and dizziness. People with certain medical conditions, such as kidney or liver disease, should not take NSAIDs without consulting their doctor. Companies in the OTC NSAID market include Bayer, Pfizer, GlaxoSmithKline, Novartis, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.